Genmab A/S · OMXCOP:GMAB
Genmab A/S — Q1 2009 Earnings Presentation
6 slides from Genmab A/S's earnings presentation, 2009
Slide 1: Interim Report First Quarter 2009
Interim Report First Quarter 2009
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, inclu
Slide 3: Key Data
Key Data 3 Months ended March 31, 2009 Q1 Q1 Q1 Q1 2009 2008 2009 2008 DKK millions USD millions * Revenue 252 167 45 30 Net Loss (199) (210) (36) (38) Manufacturing employees 160 165 160 165 All Other employees 372 405 372 405 Employees at quarter end 532 570 532 570 Cash and marketable securities
Slide 4: Income Statement
Income Statement 3 Months ended March 31, 2009 2009 2008 2009 2008 DKK millions USD millions * Revenue 252 167 45 30 Cost of Sales (2) (1) 0 - R&D Costs (296) (328) (53) (59) G&A Expenses (40) (35) (7) (6) Operating Expenses (338) (364) (60) (65) Operating Loss (86) (197) (15) (35) Net Financial Ite
Slide 5: Guidance
Guidance 2009 No change to Guidance DKK USD Millions Millions * Revenue 1,200 214 Operating Expenses 1,600 285 Operating Loss (400) (71) Year-End Cash ** 1,250 223 Cash Decrease 500 89 * USD 1.00 = DKK 5.5968 (Danish Central Bank spot rate on March 31, 2009) ** Cash, cash equivalents and marketable
Slide 6: Highlights
Highlights Business and Scientific Achievements Ofatumumab CLL BLA filed January 30 CLL MAA filed February 5 MAA accepted February 25, DKK 58 M BLA accepted March 30, DKK 87 M Granted orphan drug designation in EU and US FDA granted priority review $4.5 M co-promote termination payment Zalutumumab P